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Abstract
Background: Proteolytic degradation has emerged as a key pathway involved in controlling levels
of the Alzheimer's disease (AD)-associated amyloid-β (Aβ) peptide in the brain. The
endopeptidase, neprilysin, has been implicated as a major Aβ degrading enzyme in mice and
humans. Previous short and intermediate term studies have shown the potential therapeutic
application of neprilysin by delivering this enzyme into the brain of APP transgenic mice using gene
transfer with viral vectors. However the effects of long-term neprilysin gene transfer on other
aspects of Aβ associated pathology have not been explored yet in APP transgenic mice.
Results: We show that the sustained expression of neprilysin for up to 6 months lowered not only
the amyloid plaque load but also reduced the levels of intracellular Aβ immunoreactivity. This was
associated with improved behavioral performance in the water maze and ameliorated the dendritic
and synaptic pathology in the APP transgenic mice.
Conclusion: These data support the possibility that long-term neprilysin gene therapy improves
behavioral and neurodegenerative pathology by reducing intracellular Aβ.
Background
Alzheimer's disease (AD) is a progressive neurodegenera-
tive disorder affecting the elderly and is the most common
form of dementia [1]. Synaptic pathology is an early indi-
cator of neurodegeneration in the brains of patients with
AD [2-4] and in amyloid precursor protein (APP) trans-
genic (tg) mice [5]. Damage to the nerve terminals is
strongly correlated with the severity of the cognitive
impairment in patients with AD [2-4]. A key mediator of
this disease is believed to be the accumulation of amyloid-
β (Aβ) peptides, produced by proteolytic processing of the
APP, in the central nervous system [6]. Most recent studies
indicate that Aβ oligomers rather than fibrils are responsi-
ble for the synaptic pathology in AD [7-9] and other lines
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of investigation also support a role for intraneuronal accu-
mulation of Aβ in neurodegeneration [10-13].
Extracellular and intracellular accumulation of Aβ pep-
tides might result from alterations in the balance between
production, aggregation and degradation [14]. Mutations
in the APP and presenillin-1 (PS1) genes have been found
to be associated with familial/heritable forms of early-
onset AD by increasing the production of Aβ peptides,
which has greatly added to our understanding of potential
mechanisms leading to aberrant anabolism of Aβ [15-19].
However, the mechanisms of catabolism and clearance of
Aβ are less well understood. Endopeptidases, which
directly degrade Aβ, have emerged as important players in
the homeostatic control of this peptide. Neprilysin (NEP
or EC 3.4.24.11) is a zinc metalloendopeptidase that can
degrade Aβ [20], and has been identified as a critical Aβ
degrading enzyme in the brain [21,22]. Several groups
have also reported an inverse correlation between the
presence of NEP at the protein or RNA levels and vulnera-
bility to amyloid deposition in both mice and humans
[23-30].
The genetic linkage of the NEP gene to AD is currently
unclear as several groups have reported no association
[31,32], while more have identified an association with
the disease [33-36]. Furthermore, chemical inhibition of
NEP was shown to result in rapid accumulation of Aβ and
pathological deposition in rodents [21,37]. Previously we
and other groups have shown that the overexpression of
NEP in APP tg mice by gene transfer [38-41], transgenesis
[42], or induction [43] resulted in a reduction of Aβ accu-
mulation, neurodegeneration and behavioral deficits.
Moreover, the upregulation of NEP by somatostatin or by
environmental enrichment has been reported to reduce
Aβ levels in vitro and in vivo [44,45]. Conversely, reduced
NEP expression results in amyloid plaque deposition and
amyloid angiopathy [46] as well as accumulation of Aβ in
the synapses and behavioural deficits [47].
These findings outline the potential application of NEP
augmentation to treat AD. However, most previous gene
transfer studies with NEP have been for short or interme-
diate periods of time [38-40,48,49] and the effects of
long-term NEP gene transfer on other aspects of Aβ-asso-
ciated pathology need to be explored in APP tg mice.
Among them, recent evidence suggests that accumulation
of intracellular Aβ might also play a role in neurodegener-
ation in transgenic models and in AD [10-13]. We show
that the sustained expression of NEP with a lentiviral vec-
tor (LV) for up to 6 months, in addition to lowering the
amyloid plaque load, reduced the levels of intracellular
Aβ immunoreactivity. This was associated with improved
behavioral performance in the water maze and amelio-
rated the dendritic and synaptic pathology in the APP tg
mice. These data support the possibility that long-term
NEP gene therapy improves behavioral and neurodegen-
erative pathology by reducing intracellular Aβ.
Results
Long-term neprilysin gene transfer reduces the 
accumulation of intracellular Aβ
Our previous study has shown that NEP gene transfer
reduces synaptic damage [38]; however, the long-term
effects of NEP in other aspects of Aβ pathology and neu-
rodegeneration are less well known. First, to verify that
NEP was expressed for the term of the study, immunocy-
tochemical analysis was performed. This study confirmed
that in mice that received bilateral injections with LV-NEP
at 6 months of age, high levels of NEP expression from the
lentiviral vector were detected after 6 months (12 months
of age) in the frontal cortex and hippocampus (Fig. 1A–F).
Double labelling studies confirmed that in APP tg mice
that received LV-NEP injections, the neuronal cells over-
expressing APP also expressed NEP from the lentivirus
(Fig. 1G–I). The immunoblot analysis confirmed higher
levels of NEP immunoreativity in the mice that received
the LV-NEP injections compared to LV-empty vector con-
trol (Fig. 1J,K). The expression of NEP in the mice injected
with LV-NEP resulted in reduced Aβ levels but no effects
were observed in full length APP or C-terminal fragments
(Fig. 1J,L). The increased levels of NEP immunoreactivity
(Fig. 1K) in the LV-NEP injected mice were associated with
increased NEP activity compared to the LV-empty vector
control and the LV-NEPX (Fig. 1M). The difference in the
increase of Nep protein (3 fold) and the increase in Nep
activity (1.5 fold) probably represents the kinetics of the
enzyme activity of neprilysin cleavage of Aβ.
Neuropathological analysis showed that long-term treat-
ment with the LV-NEP reduced levels of amyloid deposi-
tion by 48% in the neocortex and 25% in the
hippocampus, compared to APP tg mice treated with LV-
empty or LV-NEPX (Fig. 2A–G). Although reduced amy-
loid load is a good indicator of the effects of NEP in this
model, amyloid plaques are poorly correlated with cogni-
tive deficits [50,51]. Since recent studies suggest that in
addition to the oligomers, accumulation of intracellular
Aβ might contribute to neurodegeneration [10-13], we
analyzed the levels of neuronal Aβ immunoreactivity with
the 4G8 antibody. Image analysis demonstrated that com-
pared to LV-empty and LV-NEPX, the LV-NEP had a pro-
found effect in reducing intracellular Aβ
immunoreactivity in pyramidal neurons in the neocortex
and hippocampus (Fig. 3A–D). An antibody against the
N-terminus of Aβ (clone 82E1) showed similar effects of
the LV-NEP reducing levels of intracellular Aβ (Fig. 3E–
H). To differentiate the intracellular APP from the Aβ
immunoreactive granules, double-labelling studies in the
brains of the APP tg mice were performed. About 45% ofBMC Neuroscience 2008, 9:109 http://www.biomedcentral.com/1471-2202/9/109
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the neurons that displayed human APP (8E5) contained
abundant Aβ immunoreactive (4G8) granules, that in
some cases co-localized (Fig. 4A–C). However, there were
also neuronal cell bodies with abundant Aβ immunoreac-
tive granules and few or no human APP immunoreactive
granules (Fig. 4A–C). This may reflect differences in cellu-
lar expression of the β-secretase enzyme involved in the
production of Aβ. Similarly results were obtained with the
antibody against the N-terminus of Aβ (82E1) and hAPP
(8E5) (Fig. 4D–F). Thus the reduction in 4G8 immunos-
taining we observed in the LV-NEP treated APP tg mice
correlates with a reduction in intracellular Aβ.
Long-term treatment with LV-NEP ameliorates water 
maze deficits in APP tg mice
APP tg mice received bilateral injections into the frontal
cortex and hippocampus with LV-NEP, or controls (LV-
NEPX and LV-empty) and were analyzed in the water
maze 6 months later. During the training part of the test
when the platform is visible, mice from all 3 groups per-
formed at comparable levels (Fig. 5A). Consistent with
results from previous studies [52], at this age APP tg mice
injected with LV-empty or the inactive LV-NEPX construct
displayed performance deficits in the spatial learning part
of the test compared to non-tg controls when the platform
was hidden (Fig. 5A). In contrast, mice that received LV-
NEP showed improved performance (Fig. 5A). At the end
of the test when the platform was visible again, mice from
all groups performed similarly (Fig. 5A). Similarly in the
probe test, when the platform was removed from the
pool, mice that received LV-NEP stayed in the target area
for a longer time compared to APP tg mice injected with
LV-NEPX or LV-empty (Fig. 5B).
The effects of LV-NEP on water maze performance and 
neurodegeneration are associated with reduced 
intracellular Aβ accumulation
Previous studies have shown that this line of APP tg mice
undergo a progressive loss of dendrites (MAP2) and pre-
synaptic (synaptophysin) nerve terminals over time
[52,53]. Therefore, we investigated the possibility that
long-term treatment with LV-NEP might ameliorate this
Immunocytochemical analysis of the levels of NEP expression in brains of APP tg mice that received lentiviral injection Figure 1
Immunocytochemical analysis of the levels of NEP expression in brains of APP tg mice that received lentiviral 
injection. Panels A-F represent images obtained by LSCM with sections from APP tg mice (12 m/o) injected into the hippoc-
ampus and neocortex. (A) Baseline levels of endogenous NEP expression. (B) Increased expression of NEP in the neocortex 
and hippocampus of mice injected with LV-NEP. (C) Animals that received injections with LV-NEPX expressed levels of NEP 
comparable to animals injected with LV-NEP. (D-F) Higher magnification views of neurons in the neocortex showing the 
increased expression of NEP in LV-NEP injected animals. (G-I) Double-labelling confocal analysis demonstrating colocalization 
of NEP (red channel) in neurons expressing human APP (green channel) in the APP tg mice injected with LV-NEP. Bar is (A-C) 
200 μm, (D-F) 10 μm, (G-I) 7 μm. (J-L) Western blot and image analysis of levels of NEP and APP/Aβ (6E10 and CT15) immu-
noreactivity in APP tg mice treated with lentiviruses. (M) Levels of NEP activity in the cortex of APP tg mice treated with lenti-
viruses. *p < 0.05 compared to LV-empty by one-way ANOVA with post-hoc Dunnett's, n = 8 mice per groupBMC Neuroscience 2008, 9:109 http://www.biomedcentral.com/1471-2202/9/109
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neurodegenerative pathology. In APP tg mice injected
with LV-NEP, MAP2 immunoreactivity was 21% higher in
the neocortex and 28% in the hippocampus compared to
APP tg mice treated with empty LV-vector or LV-NEPX (p
< 0.01) (Fig. 6A–E). Synaptophysin immunoreactivity was
increased by 18% in the neocortex and 21% in hippocam-
pus of mice infected with LV-NEP as compared to APP tg
mice treated with empty LV-vector or LV-NEPX (p < 0.05)
(Fig. 6F–J). This improved density of immunoreactivity
for MAP2 and synaptophysin was similar to age matched
non-tg mice (Fig 6A, F). Moreover, increased levels of
MAP2 and synaptophysin immunoreactivity correlated
with the performance in the water maze (Fig. 7A, B). The
levels of amyloid load were poorly correlated with the
average performance in the hidden platform phase; in
contrast, improved performance in the water maze was
significantly correlated with reduced levels of intracellular
Aβ immunoreactivity in pyramidal neurons (Fig. 7C, D).
Discussion
The present study showed that long-term gene therapy
with LV-NEP for up to 6 months improved behavioral per-
formance and ameliorated the dendritic and synaptic
pathology in APP tg mice by reducing the levels of intrac-
ellular Aβ immunoreactivity. Previous studies have been
focused at analyzing the short-term effects (1 month) of
NEP in behavioral deficits and amyloid accumulation in
APP tg mice. These studies have shown that delivery of
NEP into the hippocampus of APP tg mice by LV, adeno-
viral-associated viral vectors (AAV) or herpes simplex viral
(HSV) vectors can reduce numbers of plaques as well as
overall Aβ levels in the CNS [38,39,48,49]. AAV delivered
Nep showed localization of the protein at the presynaptic
sites whereas with the lentivirus we observed localization
to the cell soma and the ER. The reason for this difference
in cellular localization is not clear, however it may have to
do with the presence of the WPRE translation signal
present in the lentivirus vector we used that was not used
in the AAV experiments [39]. Similar protein localization
differences have been observed for GFP when comparing
these two vectors [14].
The vector-delivered NEP resulted in behavioral improve-
ments in the mice. In addition to these studies, recent
studies where LV-NEP was delivered into the hippocam-
pus of 3-month old mice showed a reduction in plaques
and overall Aβ levels in the CNS as well as improvements
in behavior after 4 months [54]. The latter study was per-
formed in mPrP-APP695 mutant mice crossed to preseni-
lin 1 mutant mice [55]. These mice develop plaques and
Neuropathological analysis of Aβ deposit immunoreactivity in the brains of APP tg mice treated with LV-NEP Figure 2
Neuropathological analysis of Aβ deposit immunoreactivity in the brains of APP tg mice treated with LV-NEP. 
(A-C) Low power view (20×) images of extracellular amyloid deposits obtained in the neocortex by LSCM with sections immu-
nostained with an antibody against Aβ (6E10) from the brains of APP tg mice (12 m/o) injected with LV-empty (A), LV-NEP (B) 
and LV-NEPX (C). (D-F) Higher power view of the amyloid deposits (600×). (G) Image analysis of the percent area of the 
neuropil occupied by Aβ-immunoreactive deposits shows a significant decrease in mice treated with LV-NEP. *p < 0.05 com-
pared to LV-empty by one-way ANOVA with post-hoc Dunnett's, n = 8 mice per group.BMC Neuroscience 2008, 9:109 http://www.biomedcentral.com/1471-2202/9/109
Page 5 of 12
(page number not for citation purposes)
accumulate Aβ at a much greater rate than previous mouse
models utilized in the field. For the present study we uti-
lized a more clinically relevant APP tg mouse model [5].
Although mice do not develop the full spectrum of AD,
they mimic the human disease in that they develop
plaques and display Aβ accumulation and age-dependent
synaptic pathology [5,56] and behavioral deficits at a
slower rate compared to a recent study [54].
The effects of neprilysin gene therapy might be reflected in
a number of compartments, not only in the extracellular
Aβ. Although the intracellular pool might represent a
small proportion of the total Aβ it might be important in
terms of mediating neuronal cell damage [10-13]. The
reduction of intracellular Aβ could also be related to a
reduction of the extracellular Aβ, with less being endocy-
tosed. In contrast to previous studies that focused on the
numbers of plaques and total accumulated levels of Aβ
[38,39,48,49,54], we focused our study on the levels of
intracellular Aβ. While some studies have suggested that
post-transcriptionally-modified Aβ fragments [57] and
oligomers [7-9] might be responsible for the neurotoxic
effects, others have suggested that accumulation of intrac-
ellular Aβ might also play a role [10-13]. This is a concern
because recent evidence suggests that accumulation of
intracellular Aβ may play a role in neuronal dysfunction
and degeneration by disturbing ERK-CREB signalling and
increasing intracellular calcium levels [12,58].
We found that levels of intracellular Aβ were reduced in
areas where the LV-NEP was injected. Moreover, the
reduction in intracellular Aβ immunoreactivity correlated
with the improved behavioral performance in the mice.
This is consistent with a study in Drosophila that showed
that overexpression of NEP reduces the pathology associ-
ated with tg expression of intracellular Aβ1–42 [59]. The
Neuropathological analysis of intracellular Aβ immunoreactivity in the brains of APP tg mice treated with LV-NEP Figure 3
Neuropathological analysis of intracellular Aβ immunoreactivity in the brains of APP tg mice treated with LV-
NEP. (A-C) Images of intracellular Aβ immunoreactivity obtained in the neocortex with the sections immunostained with an 
antibody against Aβ (4G8) from the brains of APP tg mice (12 m/o) injected with LV-empty (A), LV-NEP (B) and LV-NEPX (C). 
(D) Image analysis of the levels of intracellular Aβ-immunoreactivity shows a significant decrease in mice treated with LV-NEP. 
(E-G) Images of intracellular Aβ immunoreactivity obtained in the neocortex with the sections immunostained with an anti-
body against Aβ (82E1). (H) Image analysis of the levels of intracellular Aβ-immunoreactivity. *p < 0.05 compared to LV-empty 
or LV-NEPX by one-way ANOVA with post-hoc Dunnett's, n = 8 mice per group. Bar is (A-C) 20 μm, (E-G) 10 μm.BMC Neuroscience 2008, 9:109 http://www.biomedcentral.com/1471-2202/9/109
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mechanisms through which NEP might reduce intracellu-
lar Aβ are not clear, however NEP is a membrane-bound
enzyme that is distributed both in the plasma membrane
and endo-membrane system [60]. Thus, interactions
might occur at the endoplasmic reticulum where previous
studies have shown that intracellular Aβ accumulates [10-
13].
It has become increasingly clear in recent years that NEP
may be an important player in the treatment of AD. Sev-
eral genetic linkage studies have now reported an associa-
tion between NEP polymorphisms and risk for AD [33-
36]. Furthermore, a potential mechanism has been identi-
fied by which NEP down-regulation with age can increase
vulnerability to amyloid pathology via reduced levels of
somatostatin [44]. In addition, NEP levels and activity are
significantly reduced in the brains of AD patients [30,61-
63]. Therefore, replacement therapy might require long-
term NEP delivery, which might raise concerns about pos-
sible toxic effects. For this reason, we extended our studies
Double immunolabelling analysis of intracellular Aβ immunoreactivity in the brains of APP tg mice Figure 4
Double immunolabelling analysis of intracellular Aβ immunoreactivity in the brains of APP tg mice. (A-C) 
Images of intracellular APP and Aβ immunoreactivity obtained in the neocortex with sections immunostained with an antibody 
against Aβ (4G8) (red) and APP (8E5)(green) from the brains of APP tg mice (12 m/o). (D-F) Images of intracellular APP and Aβ 
immunoreactivity in sections immunostained with an antibody against Aβ (82E1) (red) and APP (8E5)(green). Co-localization of 
the Aβ and APP staining is identified with a white arrow. Cells staining for APP alone are denoted with a yellow arrow, and 
cells staining for Aβ alone are denoted with a asterisk. Bar is (A-C) 10 μm, (D-F) 5 μm.BMC Neuroscience 2008, 9:109 http://www.biomedcentral.com/1471-2202/9/109
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to a 6-month duration of therapy. It is important to
emphasize that compared to others, in our study injec-
tions were placed both in the hippocampus and neocortex
and we also analyzed the integrity of the neuronal struc-
ture with antibodies against synaptophysin and MAP2.
Conclusion
The present study confirmed that long-term LV-NEP amel-
iorated the neurodegenerative pathology in APP tg mice
that was associated with improved water maze perform-
ance. It is worth noting that the local levels of the LV-
driven transgene expression are relatively low and it is
unclear if much higher levels of expression for a long time
might have undesired side effects. Future studies will be
needed to address this issue.
In conclusion, these data support the possibility that long-
term NEP gene therapy improves behavioral and neurode-
generative pathology by reducing intracellular Aβ and
support the potential for NEP augmentation in the treat-
ment of AD.
Methods
Preparation of lentiviral vectors
Design of LV constructs was described previously [38]. We
produced LV expressing NEP or NEPX (an inactive ver-
sion, bearing a point mutation E585V) under the control
of the CMV promoter, or empty vector (LV-empty) using
a four-plasmid transfection system, as previously
described [64-66]. Briefly, 293T cells were transfected
with vector and packaging plasmids, the supernatants col-
lected and vectors concentrated by centrifugation. The LV
titers were estimated by measuring the amount of HIV
p24 gag antigen by ELISA (Perkin Elmer Life Science, Bos-
ton, MA) (100,000 TU/ng p24) or by flow cytometry
using a NEP-specific antibody (56C6, Research Diagnos-
tics, Inc., Concord, MA).
Transgenic mouse generation and intracerebral injections 
of lentiviral vectors
For this study we used tg mice expressing the mutant
human amyloid precursor protein (hAPPV717F/K670M/N671L)
under the control of the platelet derived growth factor
promoter (PDAPP minigene) [5]. This line (J9M) of APP
tg mice was selected because these mice express moderate
levels of APP/Aβ and display neurodegenerative pathol-
ogy and behavioral deficits associated with Aβ1–42 produc-
tion [5]. For this purpose, 6-month old APP tg mice (n =
24) received bilateral injections with 2 μl of the LV prepa-
rations (1.5 × 107 TU) into the frontal cortex and hippoc-
ampus (using a 5 μl Hamilton syringe, 0.25 μl/min). Mice
received bilateral injections with LV-NEP (n = 8), LV-
NEPX (inactive) (n = 8), or empty LV vector (LV-empty)
Behavioral performance in the water maze of APP tg mice that received bilateral injections of LV-NEP into the neocortex and  hippocampus Figure 5
Behavioral performance in the water maze of APP tg mice that received bilateral injections of LV-NEP into 
the neocortex and hippocampus. (A) Test with the visible and submerged platform. *Significant difference on individual 
days between LV-NEP treated APP tg mice and LV-NEPX or LV-empty treated APP tg mice. **Significant difference for the 
sum/average of days 4–7 between LV-NEP treated APP tg mice and LV-NEPX or LV-empty treated APP tg mice (p < 0.05 two 
way ANOVA). (B) Probe test. Mice treated with LV-NEP showed improved behavioral performance compared to LV-empty 
and LV-NEPX. * = p < 0.05 one way ANOVA when compared to LV-NEP treated APP tg mice or Nontg mice (n = 8 mice per 
group, F = 4.987, DF = 3, p = 0.0041).BMC Neuroscience 2008, 9:109 http://www.biomedcentral.com/1471-2202/9/109
Page 8 of 12
(page number not for citation purposes)
alone (n = 8). Six months post-injection (12 months old)
mice were tested in the water maze.
Water maze testing
As previously described [67], in order to evaluate the func-
tional effects of long LV-NEP treatment in mice, groups of
APP tg animals were tested in the water maze. For this pur-
pose, a pool (diameter 180 cm) was filled with opaque
water (24°C) and mice were first trained to locate a visible
platform (days 1–3) and then a submerged hidden plat-
form (days 4–7) in three daily trials 2–3 min apart. Mice
that failed to find the hidden platform within 90 s were
placed on it for 30 s. The same platform location was used
for all sessions and all mice. The starting point at which
each mouse was placed into the water was changed ran-
domly between two alternative entry points located at a
similar distance from the platform. On day 8, another vis-
ible platform trial was performed to exclude differences in
motivation and fatigue. Time to reach the platform
(latency), path length, and swim speed were recorded
with a Noldus Instruments EthoVision video tracking sys-
tem (San Diego Instruments, San Diego, CA) set to ana-
lyze two samples per second. All experiments described
were approved by the animal subjects committee at the
University of California at San Diego (UCSD) and were
performed according to NIH recommendations for ani-
mal use.
Tissue processing
Brains were removed and divided sagittaly. One hemi-
brain was post-fixed in phosphate-buffered 4% parafor-
maldehyde (pH 7.4) at 4°C for 48 hrs and sectioned at 40
μm with a Vibratome 2000 (Leica, Germany), while the
other hemibrain was snap-frozen and stored at -70°C for
immunoblot analysis.
Analysis of APP/Aβ levels by immunoblot
For Western blot analysis, 20 μg per lane of cytosolic and
particulate fractions, assayed by the BCA method (Pierce
Biotechnology, Rockford, IL), were loaded into 4–12%
SDS-PAGE gels and blotted onto polyvinylidene fluoride
(PVDF) membranes. Blots were incubated with antibod-
ies against APP/Aβ (mouse monoclonal, clone 6E10, Sig-
net Laboratories, Dedham, MA or rabbit polyclonal, clone
CT15, personal gift of E. Koo) and NEP (mouse mono-
clonal, clone CD10, Abcam, Cambridge, MA) followed by
Effects of LV-NEP treatment on levels of neurodegeneration in APP tg mice Figure 6
Effects of LV-NEP treatment on levels of neurodegeneration in APP tg mice. (A-D) LSCM images of MAP2-immu-
noreactive dendrites in the neocortex in sections from the brains of a non-tg mouse (12 m/o) (A) or APP tg mice (12 m/o) 
injected with LV-empty (B), LV-NEP (C) and LV-NEPX (D). (E) Image analysis of the percent area of the neuropil occupied by 
MAP2 immunoreactive dendrites shows a significant increase in mice treated with LV-NEP. (F-I) LSCM images of synapto-
physin-immunoreactive terminals in the neocortex in sections from the brains of a non-tg mouse (12 m/o) (F) or APP tg mice 
(12 m/o) injected with LV-empty (G), LV-NEP (H) and LV-NEPX (I). (J) Image analysis of the percent area of the neuropil occu-
pied by synaptophysin-immunoreactive terminals shows a significant increase in mice treated with LV-NEP. *p < 0.05 compared 
to LV-empty by one-way ANOVA with post-hoc Dunnett's. Bar is 15 μmBMC Neuroscience 2008, 9:109 http://www.biomedcentral.com/1471-2202/9/109
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secondary antibodies tagged with horseradish peroxidase
(HRP, Santa Cruz Biotechnology, Inc.) and visualized by
enhanced chemiluminescence and analyzed with a Versa-
doc XL imaging apparatus (BioRad, Hercules, CA). Analy-
sis of actin levels was used as a loading control.
Analysis of NEP activity
The proteolytic activity of NEP was measured as previ-
ously described [40] using the substrate 3-dansyl-D-Ala-
Gly-p-(nitro)-Phe-Gly (DAGNPG; Sigma). Cell lysate was
incubated with 50 μM DAGNPG and 1 μM captopril (to
inhibit any ACE cleavage of DAGNPG) in a volume of 200
μl at 37°C. Reactions were stopped by heating samples to
100°C for 5 min, then centrifuging. The supernatant was
diluted into 50 mM Tris (pH 7.4) and fluorescence deter-
mined using a Victor2 multilabel plate reader (excitation
342 nm; emission 562 nm).
Analysis of Aβ levels and amyloid plaque load by 
immunocytochemistry
To evaluate the amyloid plaque load, briefly as previously
described[68], vibratome sections were incubated over-
night at 4°C with the mouse monoclonal antibody
against Aβ (clone 6E10, 1:1000, Signet Laboratories, Ded-
ham, MA) followed by fluorescein isothiocyanate (FITC)-
conjugated anti-mouse IgG (Vector Laboratories, Burlin-
game, CA). The FITC-labelled sections were imaged with
the laser scanning confocal microscope (LSCM,
Linear regression analysis between markers of neurodegeneration or amyloid accumulation and behavioral performance Figure 7
Linear regression analysis between markers of neurodegeneration or amyloid accumulation and behavioral 
performance. (A, B) The average water maze performance in the hidden platform was correlated with the percent area of 
the neuropil covered by MAP2-immunoreactive dendrites and synaptophysin-immunoreactive terminals. (C, D) While amyloid 
plaques were not significantly correlated with water maze performance, levels of intracellular Aβ immunoreactivity were signif-
icantly correlated.BMC Neuroscience 2008, 9:109 http://www.biomedcentral.com/1471-2202/9/109
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MRC1024, BioRad) as described previously [5]. Digitized
images were analyzed with the NIH Image 1.43 program
to determine the percent area of the neuropil occupied by
Aβ-immunoreactive deposits in the frontal cortex and hip-
pocampus. To evaluate effects on intracellular Aβ, sections
were immunolabelled with the mouse monoclonal anti-
body against Aβ (clone 4G8; 1:600, Senetek, Napa, CA)
and with the antibody against the N-terminus of Aβ (aa 1–
16; clone 82E1; Immunobiological Laboratorie Co.
Gunma, Japan) followed by incubation with secondary
biotinylated anti-mouse IgG, followed by ABC and DAB.
Sections were transferred to SuperFrost slides (Fisher Sci-
entific, Tustin, CA) and mounted under glass coverslips
with anti-fading media (Vector Laboratories). All sections
were processed under the same standardized conditions.
Three immunolabelled sections were analyzed per mouse
and the average of individual measurements was used to
calculate group means.
Analysis NEP expression, double immunolabelling and 
neurodegeneration
To verify the expression levels of NEP, vibratome sections
were immunolabelled with a monoclonal antibody
against NEP (CD10, 1:10,000, Abcam, Cambridge, MA)
detected with the Tyramide Signal Amplification™-Direct
(Red) system (1:100, NEN Life Sciences, Boston, MA). To
evaluate the co-localization between APP and NEP, or the
intracellular distribution of APP and Aβ double immuno-
cytochemical analysis was performed as previously
described [69]. For this purpose, vibratome sections were
immunolabelled with a monoclonal antibody against
NEP (1:10,000, Abcam) or Aβ (clone 4G8; 1:600, Senetek,
Napa, CA) detected with the Tyramide Signal Amplifica-
tion™-Direct (Red) system (1:100, NEN Life Sciences, Bos-
ton, MA) and the mouse monoclonal antibodies against
human APP (1:500, 8E5 clone, Elan Pharmaceuticals,
South San Francisco, CA) detected with FITC-conjugated
secondary antibodies (1:75, Vector Laboratories) [69]. All
sections were processed simultaneously under the same
conditions and experiments were performed twice to
assess reproducibility. Sections were imaged with a Zeiss
63× (N.A. 1.4) objective on an Axiovert 35 microscope
(Zeiss, Germany) with an attached MRC1024 LSCM sys-
tem (BioRad) [69]. To confirm the specificity of primary
antibodies, control experiments were performed where
sections were incubated overnight in the absence of pri-
mary antibody (deleted) or preimmune serum and pri-
mary antibody alone.
The integrity of the neuronal structure was evaluated as
previously described [68,70]; briefly, blind-coded, 40-μm
thick vibratome sections from mouse brains fixed in 4%
paraformaldehyde were immunolabelled with the mouse
monoclonal antibodies against synaptophysin (synaptic
marker, 1:20, Chemicon, Temecula, CA) and microtubule
associated protein-2 (MAP2, dendritic marker, 1:40,
Chemicon). After overnight incubation with the MAP2
and synaptophysin, sections were incubated with FITC-
conjugated horse anti-mouse IgG secondary antibody
(1:75, Vector Laboratories), transferred to SuperFrost
slides (Fisher Scientific) and mounted under glass cover-
slips with anti-fading media (Vector Laboratories). All sec-
tions were processed under the same standardized
conditions. The immunolabelled blind-coded sections
were serially imaged with the LSCM (MRC1024, BioRad)
and analyzed with the Image 1.43 program (NIH), as pre-
viously described [71,72]. For each mouse, a total of 3 sec-
tions were analyzed and for each section, 4 fields in the
frontal cortex and hippocampus were examined. For syn-
aptophysin and MAP2, results were expressed as percent
area of the neuropil occupied by immunoreactive termi-
nals and dendrites.
Statistical analyses
Analyses were carried out with the StatView 5.0 program
(SAS Institute Inc., Cary, NC). Differences among means
were assessed by one-way ANOVA with post-hoc Dun-
nett's or Tukey-Kramer tests. All values in the figures are
expressed as means ± SEM. Comparisons between 2
groups were done with the unpaired two-tailed Student's
t-test. Correlation studies were carried out by simple
regression analysis and the null hypothesis was rejected at
the 0.05 level. To evaluate the effects of interactions
between genotype and treatment 2-way ANOVA was used
with the SuperANOVA software package (SAS Institute
Inc., Cary, NC).
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